Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing

An estimated 60% of all human genes undergo alternative splicing, a highly regulated process that pro, duces splice variants with different functions. Such variants have been linked to a variety of cancers, and genetic diseases such as thalassemia and cystic fibrosis. This Perspective describes a promising approach to RNA repair based on the use of antisense oligonucleotides to modulate alternative splicing and engender the production of therapeutic gene products.